IR@PKUHSC  > 北京大学药学院  > 药剂学系
学科主题临床医学
Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy
Wang, Ying-hui1; Wang, Li1; Lu, Wei2; Shang, De-wei2; Wei, Min-ji1; Wu, Ye1
关键词Levetiracetam Epilepsy Population Pharmacokinetics Pediatric Chinese Children
刊名ACTA PHARMACOLOGICA SINICA
2012-06-01
DOI10.1038/aps.2012.57
33期:6页:845-851
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Chemistry, Multidisciplinary ; Pharmacology & Pharmacy
研究领域[WOS]Chemistry ; Pharmacology & Pharmacy
关键词[WOS]REFRACTORY PARTIAL SEIZURES ; ADD-ON THERAPY ; HPLC-UV ; VALPROATE ; PLASMA ; DRUGS
英文摘要

Aim: To establish a population pharmacokinetics (PPK) model of levetiracetam in Chinese children with epilepsy.

Methods: A total of 418 samples from 361 epileptic children in Peking University First Hospital were analyzed. These patients were divided into two groups: the PPK model group (n=311) and the PPK validation group (n=50). Levetiracetam concentrations were determined by HPLC. The PPK model of levetiracetam was established using NONMEM, according to a one-compartment model with first-order absorption and elimination. To validate the model, the mean prediction error (MPE), mean squared prediction error (MSPE), root mean-squared prediction error (RMSPE), weight residues (WRES), and the 95% confidence intervals (95% CI) were calculated.

Results: A regression equation of the basic model of levetiracetam was obtained, with clearance (CL/F)=0.988 L/h, volume of distribution (V/F)=12.3 L, and K-a=1.95 h(-1). The final model was as follows: K-a=1.56 V/F=12.1 (L), CL/F=1.04x(WEIG/25)(0.563)(L/h). For the basic model, the MPE, MSPE, RMSPE, WRES, and the 95%CI were 9.834 (-0.587-197.720), 50.919 (0.012-1286.429), 1.680 (0.021-34.184), and 0.0621 (-1.100-1.980). For the final model, the MPE, MSPE, RMSPE, WRES, and the 95% CI were 0.199 (-0.369-0.563), 0.002082 (0.00001-0.01054), 0.0293 (0.001-0.110), and 0.153 (-0.030-1.950).

Conclusion: A one-compartment model with first-order absorption adequately described the levetiracetam concentrations. Body weight was identified as a significant covariate for levetiracetam clearance in this study. This model will be valuable to facilitate individualized dosage regimens.

语种英语
WOS记录号WOS:000305034500017
项目编号2009-2021
资助机构UCB Pharma (Braine-l&prime ; Alleud, Belgium) ; Capital Development Fund of Medical Research of China
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52490
专题北京大学药学院_药剂学系
北京大学第一临床医学院_儿科
作者单位1.Peking Univ, Hosp 1, Dept Pediat, Beijing 100034, Peoples R China
2.Peking Univ, Dept Pharmaceut, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Wang, Ying-hui,Wang, Li,Lu, Wei,et al. Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy[J]. ACTA PHARMACOLOGICA SINICA,2012,33(6):845-851.
APA Wang, Ying-hui,Wang, Li,Lu, Wei,Shang, De-wei,Wei, Min-ji,&Wu, Ye.(2012).Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy.ACTA PHARMACOLOGICA SINICA,33(6),845-851.
MLA Wang, Ying-hui,et al."Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy".ACTA PHARMACOLOGICA SINICA 33.6(2012):845-851.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Ying-hui]的文章
[Wang, Li]的文章
[Lu, Wei]的文章
百度学术
百度学术中相似的文章
[Wang, Ying-hui]的文章
[Wang, Li]的文章
[Lu, Wei]的文章
必应学术
必应学术中相似的文章
[Wang, Ying-hui]的文章
[Wang, Li]的文章
[Lu, Wei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。